Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer
Takuya Tsujino, Tomoaki Takai, Kunihiko Hinohara, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 56

Showing 1-25 of 56 citing articles:

Exploring treatment options in cancer: Tumor treatment strategies
Beilei Liu, Hongyu Zhou, Licheng Tan, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 186
Comprehensive review of CRISPR-based gene editing: mechanisms, challenges, and applications in cancer therapy
Mohammad Chehelgerdi, Matin Chehelgerdi, Milad Khorramian‐Ghahfarokhi, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 69
New clinical trial design in precision medicine: discovery, development and direction
Xiao-Peng Duan, Bao‐Dong Qin, Xiao‐Dong Jiao, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 53
Heterogeneity of the Treatment Effect with PARP Inhibitors in Metastatic Castration-resistant Prostate Cancer: A Living Interactive Systematic Review and Meta-analysis
Syed Arsalan Ahmed Naqvi, Irbaz Bin Riaz, Arifa Bibi, et al.
European Urology (2025)
Closed Access | Times Cited: 4
BRCAness, DNA gaps, and gain and loss of PARP inhibitor–induced synthetic lethality
Xin Li, Lee Zou
Journal of Clinical Investigation (2024) Vol. 134, Iss. 14
Open Access | Times Cited: 13
Olaparib research update: mechanism, structure and clinical trials
Hao Che, Liwei Wang, Xiang‐Yang Ye, et al.
Medicinal Chemistry Research (2025)
Closed Access | Times Cited: 1
Pharmacological depletion of RNA splicing factor RBM39 by indisulam synergizes with PARP inhibitors in high-grade serous ovarian carcinoma
Yuewei Xu, Sarah Spear, Yurui Ma, et al.
Cell Reports (2023) Vol. 42, Iss. 10, pp. 113307-113307
Open Access | Times Cited: 18
PARP Inhibitors for Prostate Cancer: Tangled up in PROfound and PROpel (and TALAPRO-2) Blues
Nick Beije, Wassim Abida, Emmanuel S. Antonarakis, et al.
European Urology (2023) Vol. 84, Iss. 3, pp. 253-256
Closed Access | Times Cited: 17
Discovery of the Potent and Selective ATR Inhibitor Camonsertib (RP-3500)
W. Cameron Black, Abbas Abdoli, Xiuli An, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 4, pp. 2349-2368
Closed Access | Times Cited: 8
Long non-coding RNAs in drug resistance across the top five cancers: Update on their roles and mechanisms
Yue Shi, Joseph Adu‐Amankwaah, Qizhong Zhao, et al.
Heliyon (2024) Vol. 10, Iss. 5, pp. e27207-e27207
Open Access | Times Cited: 8
Intensification Approaches and Treatment Sequencing in Metastatic Castration-resistant Prostate Cancer: A Systematic Review
Edoardo Francini, Neeraj Agarwal, Elena Castro, et al.
European Urology (2024) Vol. 87, Iss. 1, pp. 29-46
Closed Access | Times Cited: 6
Preclinical Anticipation of On- and Off-Target Resistance Mechanisms to Anti-Cancer Drugs: A Systematic Review
Paulina J. Dziubańska-Kusibab, Ekaterina Nevedomskaya, Bernard Haendler
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 2, pp. 705-705
Open Access | Times Cited: 5
p53/E2F7 axis promotes temozolomide chemoresistance in glioblastoma multiforme
Meng Jiao, Wei Qian, Zhenkun Yang, et al.
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 5
State of the art CRISPR-based strategies for cancer diagnostics and treatment
Emma Di Carlo, Carlo Sorrentino
Biomarker Research (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 4
Poly(ADP-ribose) polymerase inhibitors in cancer therapy
Zi-Qi Zhu, Yujun Shi
Chinese Medical Journal (2025)
Open Access
Targeting FEN1/EXO1 to enhance efficacy of PARP inhibition in triple-negative breast cancer
Mallory I. Frederick, Elicia Fyle, Anna Clouvel, et al.
Translational Oncology (2025) Vol. 54, pp. 102337-102337
Closed Access
Empowering PARP inhibition through rational combination: Mechanisms of PARP inhibitors and combinations with a focus on the treatment of metastatic castration-resistant prostate cancer
Jinge Zhao, Bo Tang, Pengfei Shen, et al.
Critical Reviews in Oncology/Hematology (2025), pp. 104698-104698
Closed Access
Deciphering the mechanisms of PARP inhibitor resistance in prostate cancer: Implications for precision medicine
Cheng Wang, Xiaoran Han, Shaoqiu Kong, et al.
Biomedicine & Pharmacotherapy (2025) Vol. 185, pp. 117955-117955
Closed Access
Genome-wide CRISPR activation screen identifies ARL11 as a sensitivity determinant of PARP inhibitor therapy
Tengjiang Zhang, Yuan Zhang, Xuxiang Wang, et al.
Cancer Gene Therapy (2025)
Closed Access
Advances in DNA Damage Detection: Current Progress, Challenges, and Future Directions
Heeseok Kang, Hyung Joon Park, Jieun Kang, et al.
TrAC Trends in Analytical Chemistry (2025), pp. 118246-118246
Open Access
Discovery of a Recurrent Frameshift Ashkenazi Jewish Founder Mutation (F722fs) in the PARP Inhibitor–sensitive MMS22L Gene Associated with Higher Risk of Prostate Cancer
William B. Isaacs, Jun Wei, Marta Gielzak, et al.
European Urology Focus (2025)
Closed Access
PARP inhibitor response is enhanced in prostate cancer when XRCC1 expression is reduced
Kaveri Goel, Vani Venkatappa, Kimiko L. Krieger, et al.
NAR Cancer (2025) Vol. 7, Iss. 2
Open Access
Acute BRCAness induction and AR pathway blockage through CDK12/7/9 degradation enhances PARP inhibitor sensitivity in prostate cancer
Fu Gui, Baishan Jiang, Jie Jiang, et al.
Science Advances (2025) Vol. 11, Iss. 17
Closed Access
Nuclear‐Localized BCKDK Facilitates Homologous Recombination Repair to Support Breast Cancer Progression and Therapy Resistance
Haiying Liu, Jiaqian Feng, Tingting Pan, et al.
Advanced Science (2025)
Open Access
Methylstat sensitizes ovarian cancer cells to PARP-inhibition by targeting the histone demethylases JMJD1B/C
Franziska Maria Schwarz, Daniel Martin Klotz, Ruming Yang, et al.
Cancer Gene Therapy (2025)
Open Access
Page 1 - Next Page

Scroll to top